Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MJT.0000000000001848 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Manifestations.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Background: Anti-amyloid beta (Aβ) immunotherapies have recently evolved as promising treatment options in patients with early symptomatic Alzheimer's disease (AD). Meanwhile, accurate patient selection for these treatments might be challenging mirrored by strict selection criteria of the hitherto published clinical trials. Based on a real-world tertiary care sample of post-mortem validated cases, we aimed to identify the patients matching these selection criteria and their proportion showing post-mortem AD pathology.
View Article and Find Full Text PDFEvaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease.
Brain Commun
December 2024
Division of Neurology, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
Alzheimer's disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions. The central and early role of β-amyloid in the pathogenesis of Alzheimer's disease is supported by a plethora of studies including genetic analyses, biomarker research and genome-wide association studies in both familial (early-onset) and sporadic (late-onset) forms of Alzheimer's. Monoclonal antibodies directed against β-amyloid demonstrate slowing of the clinical deterioration of patients with early Alzheimer's disease.
View Article and Find Full Text PDFA cross-sectional analysis of open payments from pharmaceutical companies to memory center physicians.
J Am Geriatr Soc
December 2024
Division of Geriatric Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Background: The development of anti-amyloid monoclonal antibodies has changed the landscape of care for patients with Alzheimer's disease (AD). The potential for financial conflicts of interest (COIs) for physicians related to these medications is unknown.
Methods: A cross-sectional analysis of open payments from industry to physicians working in memory clinics was conducted.
Evaluating Donanemab: Advances and Challenges in Alzheimer Disease Treatment.
Am J Ther
November 2024
Department of Medicine, Ziauddin Medical University, Karachi, Pakistan.
Revolutionizing Alzheimer's Diagnosis and Management: The Dawn of Biomarker-Based Precision Medicine.
Dement Neurocogn Disord
October 2024
Department of Neurology, Hanyang University College of Medicine, Seoul, Korea.
Alzheimer's disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment with a special focus on the innovative role of fluid biomarkers. Pathologically, AD is marked by amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau, which lead to synaptic dysfunction, neuronal loss, and cognitive decline.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!